PURPOSE: To evaluate the efficacy of topical @entity1138 in treating conjunctival and corneal @entity5115 and @entity5 . METHODS: Seven eyes of seven @entity1 with conjunctival and corneal @entity5115 and @entity5 were treated with one drop of topical @entity1138 0.04% four times a day for 7 days in alternate weeks. The @entity1 ' charts were reviewed retrospectively. @entity1 with either multiple recurrences or extensive ocular surface involvement were treated. In all eyes, the diagnosis of @entity5115 or @entity5 was confirmed by histopathology before the onset of therapy. @entity1 were examined at least every 14 days during treatment and examined at intervals after completion of treatment. RESULTS: With topical @entity1138 , six eyes of seven @entity1 had complete clinical regression of their conjunctival and corneal @entity5115 and @entity5 . One eye of one @entity1 had partial clinical regression of conjunctival and corneal @entity5115 . Follow-up after completion of topical @entity1138 therapy and excision of @entity66 ranged from 2 to 16 months (mean, 9 months; SD, 4.3 months) and was without clinical sign of recurrence. Topical @entity1138 therapy was associated with transitory ocular discomfort, conjunctival injection, tearing, @entity3917 , and punctate epithelial keratopathy. CONCLUSION: In this small series of eyes, topical @entity1138 was effective as a treatment for conjunctival and corneal @entity5115 and @entity5 .

Topical @entity1138 for the treatment of conjunctival and corneal XXXX and @entity5 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity5115 :: ('MESH:C567703', 'Disease') :: ['epithelial dysplasia'] @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['neoplasia'] @entity1138 :: ('MESH:D016685', 'Chemical') :: ['mitomycin C'] @entity3917 :: ('MESH:D020795', 'Disease') :: ['photophobia']
@entity5115 :: (MESH:C567703,Disease) :: ['epithelial dysplasia']
